and acquisitions of Indian pharmaceutical companies
The major reason for acquisitions is to attaining access to new technologies, clinical research, catapulting the market share and platform for improving custom synthesis and working with new clients. The major companies acquiring acquisitions in India are Ranbaxy, Dr. Reddy’s, Dishman and Wockhardt.
Over the last decade the outsourcing has become the important part for the pharmaceutical companies. The main reason for the outsourcing is rising pressure to reduce costs, and time-to-market, this leads to the increasing the technical demanding areas such as drug discovery and biotech R&D. Outsourcing opportunities has been rapidly growing in the market like Eastern Europe, China, India. Indian pharmaceutical industries are putting effort on the development of the product for global generic market and this will be visible with the DMF filing at the US FDA (DMFs are generic dossiers filed with the FDA in order to allow the API to appear in marketed drugs). 30% of the DMF filings at US FDA are filed by Indian companies. Dr. Reddy’s, aurobindo, cipla, Ranbaxy, matrix and lupin are the leading Indian companies of DMFs filed in US.
From the sources of US and European countries they made research on Indian based pharmaceuticals companies regarding merging and acquisitions and they were pleased to announce some name to the Indian companies and decided to name as “Indian Pharmaceutical MNC.
Mainly US and European countries have focused on Indian due to the vast change in research work done and the main plus points for them were the laws of Indian government have changed drastically like providing new opportunities to launch patented molecules this point made them interest in investing Indian pharmaceuticals, and likewise India pharma is becoming strong manufacturing stand and with low-cost development, manufacturing destination.
Source: Shivani Shukla, 2006.
The global has been rapidly changing into the generic market; here are some companies that have been invested, acquired and deals in 2008-09. Green cross Pharma in Singapore was acquired by Ascent; Pfizer plant in Ireland was acquired by Hovione, PharmaPro manufacturing facility was acquired by URL Pharma, ECR pharmaceuticals was acquired by HI-Tech pharmacal.
Source: Research and Markets, 2009.
Indian pharmaceutical market in U.S., has been continuously increasing, a $440 billion market appoints 47% of the global pharmaceutical market. In February 2009, Indian pharmaceutical companies including large and mid-sized all together have assured approvals for 15 Abbreviated New Drug Applications (ANDAs) (Indus view, 2009).
Strategies:
In order to expand their market some companies have entered into foreign markets in generic drugs segment. Some companies have entered directly by setting their own sales and marketing organisation, either in organic manner or through acquisitions and others have entered these market through partnership or merging with well established companies. Ranbaxy acquired Ohm Laboratories in US
